Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia

Habicht "Increase of infectious complications in ABO-incompatible kidney transplant recipients-a single centre experience" Nephrol Dial Transpl (2011) 10.1093/ndt/gfr215

[3]

Ferraresso "Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats" J Immunol (1994) 10.4049/jimmunol.153.7.3307

[4]

Vogelbacher "Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat" Nephrol Dial Transplant (2010) 10.1093/ndt/gfq230

[5]

Langer "Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation" Transpl Int (2012) 10.1111/j.1432-2277.2012.01465.x

[6]

Peddi "Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation" Transpl Rev (2013) 10.1016/j.trre.2013.06.001

[7]

Van Rossum "Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12" Biochem Pharmacol (2009) 10.1016/j.bcp.2008.12.009

[8]

Hirsch "BK polyomavirus in solid organ transplantation" Am J Transpl (2013) 10.1111/ajt.12110

[9]

Brennan "Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms" Rev Med Virol (2013) 10.1002/rmv.1733

[10]

Sharif "Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients" Clin J Am Soc Nephrol (2012) 10.2215/cjn.00770112

[11]

Tohme "Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients" Transpl Infect Dis (2015) 10.1111/tid.12347

[12]

Moscarelli "Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience" Clin Transpl (2013) 10.1111/ctr.12151

[13]

Carmellini "Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure" Transpl Proc (2008) 10.1016/j.transproceed.2008.05.047

[14]

Kacar "Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy" Transpl Proc (2010) 10.1016/j.transproceed.2010.08.043

[15]

Catalano "Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome" Transpl Int (2014) 10.1111/tri.12304

[16]

Uchida "Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study" Clin Transpl (2013) 10.1111/ctr.12281

[17]

Liefeldt "Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation" Am J Transpl (2012) 10.1111/j.1600-6143.2011.03961.x

[18]

Cibrik "Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation" Transplantation (2013) 10.1097/tp.0b013e3182848e03

[19]

Ponticelli "Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study" Transplantation (2011) 10.1097/tp.0b013e318216c1db

[20]

Budde "Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study" Am J Transpl (2015) 10.1111/ajt.12952

[21]

Oh "Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients" Transplantation (2015) 10.1097/tp.0000000000000225

[22]

Perbos "Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors" Clin Transpl (2014) 10.1111/ctr.12418

[23]

Murakami "Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis" Am J Transpl (2014) 10.1111/ajt.12852

[24]

Renner "The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects" Transpl Proc (2013) 10.1016/j.transproceed.2013.01.026

Metrics

22

Citations

24

References

Details

Published: Dec 16, 2015
Vol/Issue: 29(3)
Pages: 315-322
License: View

Authors

J

Julie Belliere

Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France

N

Nassim Kamar

Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France; INSERM U563; IFR-BMT; CHU Purpan; Toulouse France; University Paul Sabatier; Toulouse France

C

Catherine Mengelle

INSERM U563; IFR-BMT; CHU Purpan; Toulouse France; Department of Virology; CHU Purpan; Toulouse France

A

Asma Allal

Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France

F

Federico Sallusto

Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France

N

Nicolas Doumerc

Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France

X

Xavier Game

Department of Urology and Kidney Transplantation; CHU Rangueil; Toulouse France

N

Nicolas Congy-Jolivet

University Paul Sabatier; Toulouse France; Laboratory of Immunology; CHU Rangueil; Toulouse France

L

Laure Esposito

Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France

B

Benedicte Debiol

Etablissement Français du Sang; CHU Purpan; Toulouse France

L

Lionel Rostaing

Department of Nephrology and Organ Transplantation; University Hospital; Toulouse France; INSERM U563; IFR-BMT; CHU Purpan; Toulouse France; University Paul Sabatier; Toulouse France

Cite This Article

Julie Belliere, Nassim Kamar, Catherine Mengelle, et al. (2015). Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. Transplant International, 29(3), 315-322. https://doi.org/10.1111/tri.12718

Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia

You May Also Like